Norwegia -
Norwegia -
Statens legemiddelverk
fluanxol 1 mg
h. lundbeck a/s - flupentiksoldihydroklorid - tablett, filmdrasjert - 1 mg
Norwegia -
Norwegia -
Statens legemiddelverk
fluanxol 0.5 mg
h. lundbeck a/s - flupentiksoldihydroklorid - tablett, filmdrasjert - 0.5 mg
Norwegia -
Norwegia -
Statens legemiddelverk
fluanxol 5 mg
h. lundbeck a/s - flupentiksoldihydroklorid - tablett, filmdrasjert - 5 mg
Norwegia -
Norwegia -
Statens legemiddelverk
valsartan/hydrochlorthiazid actavis 80 mg / 12.5 mg
actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 80 mg / 12.5 mg
Norwegia -
Norwegia -
Statens legemiddelverk
valsartan/hydrochlorthiazid actavis 160 mg / 12.5 mg
actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 12.5 mg
Norwegia -
Norwegia -
Statens legemiddelverk
valsartan/hydrochlorthiazid actavis 160 mg / 25 mg
actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 25 mg
Uni Eropa -
Norwegia -
EMA (European Medicines Agency)
dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaksiner - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. bruk av dengvaxia skal være i samsvar med offisielle anbefalinger.
Norwegia -
Norwegia -
Statens legemiddelverk
capsion sodium iodide [131i] capsules for therapy 50 mbq
cis bio international - natriumjodid (131 i) - kapsel, hard - 50 mbq